Wedbush Equities Analysts Boost Earnings Estimates for Geron Co. (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Research analysts at Wedbush increased their FY2028 earnings estimates for shares of Geron in a research note issued to investors on Thursday, August 8th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will earn $0.78 per share for the year, up from their previous forecast of $0.65. Wedbush has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.35) per share.

Other equities analysts also recently issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Geron in a research note on Friday. Robert W. Baird lowered shares of Geron from an “outperform” rating to a “neutral” rating and set a $4.50 price objective on the stock. in a research report on Tuesday, April 30th. Barclays assumed coverage on Geron in a research report on Monday, June 10th. They issued an “overweight” rating and a $9.00 price objective on the stock. Stifel Nicolaus raised their price target on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, TD Cowen started coverage on shares of Geron in a research note on Monday, April 29th. They set a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Geron currently has a consensus rating of “Moderate Buy” and an average target price of $7.07.

Geron Price Performance

Geron stock traded down $0.01 during mid-day trading on Friday, reaching $4.59. The company had a trading volume of 1,482,451 shares, compared to its average volume of 11,390,769. The stock’s 50-day simple moving average is $4.54 and its 200-day simple moving average is $3.49. The company has a market capitalization of $2.72 billion, a P/E ratio of -13.23 and a beta of 0.48. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.67 and a quick ratio of 3.67. Geron has a 1 year low of $1.64 and a 1 year high of $5.34.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.88 million for the quarter, compared to analyst estimates of $0.34 million. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. The business’s revenue was up 2941.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.09) earnings per share.

Institutional Investors Weigh In On Geron

Several institutional investors have recently bought and sold shares of GERN. Vivo Capital LLC raised its position in shares of Geron by 46.1% during the 4th quarter. Vivo Capital LLC now owns 24,143,681 shares of the biopharmaceutical company’s stock worth $50,943,000 after buying an additional 7,619,047 shares in the last quarter. Farallon Capital Management LLC acquired a new stake in Geron in the first quarter worth approximately $24,734,000. Affinity Asset Advisors LLC bought a new position in Geron during the 1st quarter valued at $8,250,000. Price T Rowe Associates Inc. MD raised its stake in shares of Geron by 999.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock worth $6,815,000 after buying an additional 1,877,184 shares in the last quarter. Finally, Altitude Crest Partners Inc. bought a new position in shares of Geron during the 1st quarter valued at about $5,054,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Insiders Place Their Bets

In other news, CEO John A. Scarlett sold 600,000 shares of Geron stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $4.00, for a total transaction of $2,400,000.00. Following the sale, the chief executive officer now directly owns 600,000 shares of the company’s stock, valued at $2,400,000. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO John A. Scarlett sold 600,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.00, for a total transaction of $2,400,000.00. Following the sale, the chief executive officer now directly owns 600,000 shares of the company’s stock, valued at approximately $2,400,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Faye Feller sold 287,900 shares of Geron stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $4.63, for a total value of $1,332,977.00. The disclosure for this sale can be found here. Insiders have sold 1,562,248 shares of company stock worth $6,808,004 in the last quarter. 3.10% of the stock is owned by corporate insiders.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.